 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels.

Concord Biotech stock gains 3% as Kotak and Antique Broking issue positive coverage

Concord Biotech delivered stellar performance on its debut, rising 27 percent to settle at Rs 942.8 on the NSE, despite weakness in equity markets.

Bulk Deals: Norges Bank buys stake worth Rs 80.92 crore in Concord Biotech; Morgan Stanley picks up 1.24% in Repro India

Concord Biotech | The stock performance was much higher than analysts' expectations as well as grey market premium which was around 15 percent over the issue price.

Concord Biotech settles on debut day with 27% gains despite market correction

Most experts feel the subdued market conditions seen in the last three odd weeks had some impact on the listing performance.

Concord Biotech stock lists at 21% premium over IPO price; share price hits Rs 900 at open

Concord Biotech Ltd. operates as a research and development based biotechnology company. It manufactures active pharmaceutical ingredients through the process of fermentation, semi-synthetic and synthetic processes. The firm''s products include APIs in the immunosuppressant, antibiotic, oncology, antifungal and hypolipemic segments and enzymes. The company was founded in 2000 and is headquartered in Ahmedabad, India.

Watchers	15
52-Wk Low	900.05
52-Wk High	1,090.10

Market Cap	113.4B
Volume (M)	205,871.00
52-Wk High	1,090.10
52-Wk Low	900.05

CONCORDBIO.NSE Concord Biotech Ltd.

About

Feed

News

Fundamentals